Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99550 | 0.94 | MCHR1 (0.40) | MCHR1CDK8KDM4EPKMALDH1A1 | |
| SCHEMBL661325 | 0.86 | PDCD1 (0.36) | MCHR1CDK8KDM4EPKMALDH1A1 | |
| SCHEMBL175794 | 0.85 | CDK8 (0.42) | MCHR1CDK8 | |
| SCHEMBL661903 | 0.85 | S1PR1 (0.34) | MCHR1CDK8PKM | |
| SCHEMBL101815 | 0.84 | ALPL (0.37) | HCAR2MEN1ALDH1A1KMT2A | |
| SCHEMBL99851 | 0.84 | CHRM3 (0.48) | — | |
| SCHEMBL660644 | 0.82 | NPC1 (0.38) | MEN1ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL663422 | 0.80 | CHRM3 (0.47) | — | |
| SCHEMBL99078 | 0.80 | HCAR2 (0.42) | MCHR1HCAR2MEN1ALDH1A1LMNA | |
| SCHEMBL134109 | 0.77 | ALPL (0.36) | MEN1ALDH1A1LMNAHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | MCHR1 223/4885CDK8 4493/4885HCAR2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.